🔍 Dr Rana McKay of UC San Diego Health Sciences leads Alliance for Clinical Trials in Oncology A031801 (RadiCaL) testing if adding an new anti-cancer drug to the usual chemotherapy improves outcomes for advanced renal cell cancer. 📢 Learn more at http://bit.ly/AllianceA031801 #clinicaltrials

Nomination due Friday, July 24, for for prestigious Alliance lectureships: 1️⃣ Jimmie C. Holland Lecture (Psycho-oncology) ➡️ Due July 24, 2026 2️⃣ Charles G. Moertel Lecture (Community Practice) ➡️ Due Sept 18, 2026 Nomination info 👉 https://bit.ly/4vXnicO

Trial Tuesday! Jennifer Ligibel MD of Dana-Farber Cancer Institute and Kathryn Schmitz PhD of @upmchillmancc.bsky.social lead Alliance A222302 studying a telehealth exercise program for cancer patients with the goal of reducing fatigue and disability. https://bit.ly/DEFEND-trial #NCI #NCTN

Dr. Ugonma Chukwueke of Dana-Farber Cancer Institute leads a new Alliance trial exploring if adding a targeted medicine called vorasidenib to the usual treatment can help people with newly diagnosed IDH mutated grade 3 astrocytoma, a type of brain cancer. https://bit.ly/Brain2026 #clinicaltrials

Help the Alliance for Clinical Trials in Oncology illustrate the true face of cancer research! 📸 Member sites are invited to submit authentic, action-oriented photos of clinical care, diagnostics, surgeries, and collaborative labs. Submit by Sept 10. https://bit.ly/AlliancePhotos.

Dr. Brad McGregor of Dana-Farber Cancer Institute leads Alliance A032201 (STRIKE) to see if adding the anti-cancer drug tivozanib to the standard treatment of immunotherapy after surgery helps patients with high-risk renal cell cancer. Learn more: https://bit.ly/Alliance-A032201 #NCI #NCTN #kidney

Dr. Rana McKay from UC San Diego Health Sciences and Misha Beltran Dana-Farber Cancer Institute co-lead @ALLIANCE_org A032102/PREDICT evaluating if genetic testing helps determine the best treatment regimen for men with metastatic prostate cancer. Learn more: https://bit.ly/Alliance-A032102 #PCsm

Thomas Hope of UCSF Helen Diller Family Comprehensive Cancer Center and Deaglan McHugh of Memorial Sloan Kettering Cancer Center lead Alliance A032304 (RECIPROCAL), a prostate cancer trial studying targeted radiation to minimize side effects while preserving efficacy. https://bit.ly/AllianceA032304

New trial! The Alliance has a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma. Visit https://bit.ly/CLL-SLL to learn about Alliance A042302 led by Dr. Jennifer R. Brown of Dana-Farber Cancer Institute #clinicaltrials

AFT study in @JCOOA_ASCO shows simple weekly digital symptom check-in improves quality of life and reduces emergency room visits for patients with advanced cancer by bridging communication gaps. News release - https://bit.ly/AFT-39. Study: https://bit.ly/AFT39-JCO

Dr. Haeseong Park of Dana-Farber News leads Alliance A022102 studying mFOLFIRINOX vs mFOLFOX with or without immunotherapy drug nivolumab for metastatic HER2 negative esophageal, gastroesophageal junction and gastric cancer. More: https://bit.ly/Alliance-A022102 #ColorectalCancer #clinicaltrials

📢 New Clinical Trial: Alliance A082302 is studying if immunotherapy after surgery prevents recurrence in early non-small cell lung cancer (#NSCLC). The trial aims to enroll 336 participants to move from passive observation to active prevention. More at https://bit.ly/43SStJU.

The Alliance for Clinical Trials in Oncology is amplifying its mission in the media. Recent news stories showcase major trial results, like the success of the new PEP portal and FDA progress for breast and colon cancer. See the full June media recap at https://bit.ly/JuneMedia

🚨 Milestone reached: The ERASur colorectal cancer trial has surpassed one third patient accrual nationwide. The study is evaluating whether aggressive local therapy can improve survival in limited metastatic disease. #ClinicalTrials #ColorectalCancer https://bit.ly/ERASur26

With colorectal cancer, if a person has an inherited gene change, other family members are at risk. Alliance A212101 will see if family members are more likely to get genetic testing to catch disease early if they hear from a healthcare provider. More at https://bit.ly/CRCGene-Testing

Now enrolling! Bhavana Konda, MD, MPH, of Ohio State University leads Alliance for Clinical Trials in Oncology A092204 exploring if using two targeted drugs can help slow tumor growth in #AYA with advanced adrenocortical carcinoma, a rare cancer of the adrenal glands. https://bit.ly/A092204-Konda

Now enrolling! Dr. Deepak Kilari from Medical College of Wisconsin is now enrolling ALLIANCE A032302, the ASPIRE trial, to see if adding chemo to hormone therapy improves survival in men with metastatic #prostatecancer. To learn more, visit http://bit.ly/AllianceA032302.

👏 Big thanks to outgoing Alliance chairs Drs. John Leonard, Aminah Jatoi and George Chang for years of practice-changing cancer research! 🌟Congrats and welcome to our new leaders from @DanaFarber, @MassGenBrigham, @UCLAHealth, @MDAndersonNews and more! https://bit.ly/Leaders-2026

ERAsur has gone global! Led by Eric Miller of The Ohio State University Wexner Medical Center, Alliance A022101 aimed at improving colorectal cancer survival is active to patients in Canada with sites in Mexico, Colombia and Chile to begin this month. https://bit.ly/ERAsur Colorectal Cancer Canada

Did you know adolescents and young adults (#AYA, ages 15 to 39) represent 4% of all cancers diagnosed each year. They can be treated pediatric or adult centers, but often feel they don’t fit into either category. More info https://bit.ly/AYA2026 #AYACancerAwareness

JNCI Now article highlights the success of Alliance for Clinical Trials in Oncology secure PEP platform in a national pilot study 📊 96%: Easy to access 📊 93%: Surveys easy to compete 📊 93%: Yes to future research Read the story: https://bit.ly/PEP-JNCI Read the article: https://bit.ly/PEP-article

🎉 FDA APPROVES palbociclib combo for HR+, HER2+ advanced breast cancer! Based on the PATINA trial (AFT-38), adding palbociclib to maintenance therapy extended progression-free survival by 15 months (from 29.1 to 44.3 mos). A huge win for patient care! 💪 https://bit.ly/PATINA-FDA

Now enrolling! Dr. Gabriel Brooks of Dartmouth Cancer leads the PAGODA trial (Alliance A232402CD) aimed at reducing unplanned treatment delays in people with gastrointestinal cancers. Learn more at https://bit.ly/PAGODA26. #ColorectalCancer #OncTwitter #gism #MedTwitter #ClinicalTrials

Now enrolling! A new Alliance for Clinical Trials in Oncology trial tackles a common but overlooked side effect of breast cancer treatment. #REVITALIZE is testing laser therapy to relieve chronic vaginal dryness and improve quality of life for survivors. 💗🧪 #BCSM https://bit.ly/REVITALIZE2026

New lung cancer trial open 🧪🫁 Alliance A082402 is studying if targeted post op radiation (I² PORT) can reduce recurrence in high risk #NSCLC patients after surgery while limiting side effects. Learn more https://bit.ly/I-PORT-Trial. #LungCancer #ClinicalTrials #RadiationTherapy

Now enrolling! Sascha Tuchman, MD of UNC Lineberger Comprehensive Cancer Center leads Alliance A062102, a randomized trial comparing iberdomide maintenance therapy to disease monitoring to improve survival in patients with multiple #myeloma. More: https://bit.ly/Alliance-A062102 #clinicaltrials

Dr. Anne Beaven of UNC Lineberger Comprehensive Cancer Center leads Alliance for Clinical Trials in Oncology A052101, a trial to see if older people with mantle cell lymphoma can receive fewer treatments of the targeted cancer medicine zanubrutinib while in remission.https://bit.ly/Alliance-A052101

Sara Tolaney of Dana-Farber Cancer Institute leads Alliance A012103 for early-stage breast cancer patients with complete response after chemo+pembrolizumab. This phase III trial compares continuing pembrolizumab vs monitoring after surgery. Learn more: https://bit.ly/Alliance-A012103 #clinicaltrials

Now enrolling! Dr. Ada Waks of Dana-Farber Cancer Institute leads Alliance for Clinical Trials in Oncology A012303 (ShortStop-HER2), a phase III study testing if less treatment after surgery is an option for people with early-stage HER2+ #breastcancer. https://bit.ly/Alliance-A012303

Drs. Thomas Hope of UCSF Helen Diller Family Comprehensive Cancer Center & Suki Padda of @foxchasecancer.bsky.social lead Alliance A021901/B-LuRE trial comparing a radioactive drug to chemo in patients with bronchial #neuroendocrine tumors. More at https://bit.ly/Alliance-A021901 #clinicaltrials